[go: up one dir, main page]

MX2015009719A - Inhibidores benzoquinolona de vmat2. - Google Patents

Inhibidores benzoquinolona de vmat2.

Info

Publication number
MX2015009719A
MX2015009719A MX2015009719A MX2015009719A MX2015009719A MX 2015009719 A MX2015009719 A MX 2015009719A MX 2015009719 A MX2015009719 A MX 2015009719A MX 2015009719 A MX2015009719 A MX 2015009719A MX 2015009719 A MX2015009719 A MX 2015009719A
Authority
MX
Mexico
Prior art keywords
vmz2
inhibitors
benzoquinolone
benzoquinolone inhibitors
vmat2
Prior art date
Application number
MX2015009719A
Other languages
English (en)
Inventor
Sommer Andreas
Zhang Chengzhi
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2015009719A publication Critical patent/MX2015009719A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con nuevos inhibidores benzoquinolona de VMAT2, composiciones farmacéuticas de los mismos y métodos de uso de los mismos. (ver Fórmula).
MX2015009719A 2013-01-31 2014-01-28 Inhibidores benzoquinolona de vmat2. MX2015009719A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361758861P 2013-01-31 2013-01-31
PCT/US2014/013327 WO2014120654A1 (en) 2013-01-31 2014-01-28 Benzoquinolone inhibitors of vmat2

Publications (1)

Publication Number Publication Date
MX2015009719A true MX2015009719A (es) 2016-08-08

Family

ID=51262872

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009719A MX2015009719A (es) 2013-01-31 2014-01-28 Inhibidores benzoquinolona de vmat2.
MX2020001756A MX2020001756A (es) 2013-01-31 2015-07-28 Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001756A MX2020001756A (es) 2013-01-31 2015-07-28 Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.

Country Status (11)

Country Link
US (5) US20160068526A1 (es)
EP (3) EP3421469A1 (es)
JP (3) JP2016506957A (es)
AU (4) AU2014212586A1 (es)
BR (1) BR112015017878A2 (es)
CA (1) CA2899707A1 (es)
EA (2) EA201500801A1 (es)
HK (1) HK1219095A1 (es)
IL (3) IL240146A0 (es)
MX (2) MX2015009719A (es)
WO (1) WO2014120654A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
IN2015DN01662A (es) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
MX2016009817A (es) * 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
JP6932641B2 (ja) 2015-03-06 2021-09-08 オースペックス ファーマシューティカルズ インコーポレイテッド 異常不随意運動障害の処置のための方法
ES2972600T3 (es) 2015-10-30 2024-06-13 Neurocrine Biosciences Inc Sales de diclorhidrato de valbenazina y polimorfos de las mismas
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
WO2018130345A1 (en) 2017-01-10 2018-07-19 Sandoz Ag Crystalline valbenazine free base
JP7199359B2 (ja) * 2017-01-27 2023-01-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
US10954235B2 (en) 2017-02-27 2021-03-23 Sandoz Ag Crystalline forms of valbenazine salts
BR112020005373A2 (pt) 2017-09-21 2020-09-24 Neurocrine Biosciences Inc. formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina
SG11202003194YA (en) 2017-10-10 2020-05-28 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
AU2019362389B2 (en) 2018-10-18 2024-12-12 Oncopeptides Innovation Ab Compounds containing deuterium
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP4606429A3 (en) 2021-03-22 2025-12-03 Neurocrine Biosciences, Inc. Vmat2 inhibitors and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2843591A (en) * 1958-07-15 Method for preparing same
US2830993A (en) 1958-04-15 Quinolizine derivatives
US3045021A (en) 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
CA2186371A1 (en) * 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
PT1104760E (pt) * 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
BRPI0711481A8 (pt) 2006-05-02 2017-11-28 Univ Michigan Regents derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US8053578B2 (en) * 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
US8524733B2 (en) * 2008-09-18 2013-09-03 Auspex Pharmaceuticals Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20100113496A1 (en) * 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2

Also Published As

Publication number Publication date
HK1219095A1 (zh) 2017-03-24
EP3770159A1 (en) 2021-01-27
US20160068526A1 (en) 2016-03-10
US20200165240A1 (en) 2020-05-28
EA201500801A1 (ru) 2016-01-29
EP2951178A4 (en) 2016-07-06
JP2021100941A (ja) 2021-07-08
AU2021201629A1 (en) 2021-04-08
EP3421469A1 (en) 2019-01-02
WO2014120654A1 (en) 2014-08-07
CA2899707A1 (en) 2014-08-07
IL240146A0 (en) 2015-09-24
AU2018203477A1 (en) 2018-05-31
US20210355120A1 (en) 2021-11-18
JP2016506957A (ja) 2016-03-07
US20180208592A1 (en) 2018-07-26
US20250179064A1 (en) 2025-06-05
EP2951178A1 (en) 2015-12-09
IL279682A (en) 2021-03-01
AU2014212586A1 (en) 2015-08-06
AU2019268062A1 (en) 2019-12-12
BR112015017878A2 (pt) 2017-07-11
EA202091397A1 (ru) 2020-09-04
IL267154A (en) 2019-08-29
JP2019048829A (ja) 2019-03-28
MX2020001756A (es) 2020-07-28

Similar Documents

Publication Publication Date Title
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX374558B (es) Compuestos de heteroarilo y sus usos.
NI201500119A (es) Compuestos de heteroarilo y sus usos
CR20150462A (es) Inhibidores de erk y sus usos
MX380146B (es) Inhibidores mk2 y usos de los mismos.
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
MX2016004933A (es) Inhibidores de pirimidina del fgfr4.
DK3066085T3 (da) Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
SV2014004770A (es) Nuevos derivados de pirrol, su procedimiento de preparación y los composiciones farmacéuticas que los contienen
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
JO3773B1 (ar) معدلات p2x7
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
CR20150061A (es) Compuesto de pirazolopirimidinas
MX2017007377A (es) Compuestos organicos.
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ